Research programme: toll-like receptor 8 agonists and antagonists - VentiRx

Drug Profile

Research programme: toll-like receptor 8 agonists and antagonists - VentiRx

Alternative Names: VTX-294; VTX-378; VTX-763

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Developer VentiRx Pharmaceuticals
  • Class Benzazepines; Small molecules
  • Mechanism of Action Toll-like receptor 8 agonists; Toll-like receptor 8 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Hypersensitivity

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
  • 14 Feb 2017 VentiRx Pharmaceuticals has been acquired by Celgene Corporation
  • 05 Apr 2016 Preclinical development is ongoing in Autoimmune disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top